(Q37641606)

21 August 2017

1 reference

title

Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans (English)

1 reference

21 August 2017

1 reference

Nagy A Farid

1

1 reference

PubMed ID

19948947

21 August 2017

Atsushi Kurihara

series ordinal

2

1 reference

PubMed ID

19948947

21 August 2017

Steven A Wrighton

series ordinal

3

1 reference

21 August 2017

30 November 2009

1 reference

The Journal of Clinical Pharmacology

21 August 2017

1 reference

21 August 2017

50

1 reference

21 August 2017

126-142

1 reference

21 August 2017

2

1 reference

Optimizing platelet P2Y12 inhibition for patients undergoing PCI

21 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Rash in patients receiving ticlopidine after intracoronary stent placement

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Identification of the active metabolite of ticlopidine from rat in vitro metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Characterization of novel dihydrothienopyridinium and thienopyridinium metabolites of ticlopidine in vitro: role of peroxidases, cytochromes p450, and monoamine oxidases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Structure and stereochemistry of the active metabolite of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

The disposition of prasugrel, a novel thienopyridine, in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Stereoselective metabolism of prasugrel in humans using a novel chiral liquid chromatography-tandem mass spectrometry method

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

The human intestinal cytochrome P450 "pie".

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Ticlopidine decreases the in vivo activity of CYP2C19 as measured by omeprazole metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Proton pump inhibitors--differences emerge in hepatic metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270009343005

21 January 2018

Identifiers

DOI

10.1177/0091270009343005

1 reference

21 August 2017

1 reference

PubMed ID

19948947